Roxane Alupent Production To Be Halted While GMP Concerns Are Addressed
Executive Summary
Roxane Labs is temporarily halting production of its asthma product Alupent following receipt of a July 12 FDA warning letter on GMP deficiencies in the manufacturing of liquid drug products at its Columbus, Ohio facility.
You may also be interested in...
Third Quarter Conference Calls, In Brief
Pfizer Spiriva production: Boehringer-Ingelheim "has sufficient manufacturing capacity already in Germany" to meet demand for the chronic obstructive pulmonary drug Spiriva (tiotropium) "for out as far as we can see," Pfizer CEO Henry McKinnell tells Oct. 17 conference call. Pfizer will copromote the BI agent, with launch expected in 2002 or 2003. BI's Columbus, Ohio facility "was to come on stream for production in 2005," McKinnell noted. The plant was the subject of an FDA warning letter in July (1"The Pink Sheet" July 30, p. 10)...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011